Psoriasis Clinical Trials

Showing 621-640 of 1,026 trials

RECRUITINGPhase 4

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

NCT04347473

Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.

Psoriasis

Psoriasis Treatment Center of Central New Jersey25 participantsStarted Apr 2020

East Windsor, New Jersey, United States

UNKNOWNNA

Evaluation of the Role of Inflammatory and Structural Ultrasound Abnormalities by Explaining the Perspective of Patients With Psoriatic Arthritis

NCT04325724

The perspective of the patient is defined by the patient reported outcomes (PROs). This is a main part of the care in psoriatic arthritis. However , PROs can be influenced by environmental parameters. Ultrasound represents an objective instrument in the context of psoriatic rheumatism (RhPso) care because it measures inflammatory activity and structural damage at joint and periarticular level. it is the first study to evaluate the role of inflammatory and structural ultrasound abnormalities as a cause of modification of the patient's perspective measured by PROs in patients with RhPso.

Psoriatic Arthritis

Assistance Publique - Hôpitaux de Paris100 participantsStarted Apr 2020

COMPLETEDPhase 1

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

NCT03210961

This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.

Plaque Psoriasis

Pfizer109 participantsStarted Jul 2017

Anaheim, California, United States

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

Evaluation of the Role of Inflammatory and Structural Ultrasound Abnormalities by Explaining the Perspective of Patients With Psoriatic Arthritis

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

Related Searches

Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab

A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

Skin Tape Harvesting for Transcriptomics Analysis

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream

Efficacy and Tolerability of Enstilar® in Daily Practice

Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study

Study of Molecular Markers in Cutaneous Inflammation Between Psoriatic Lesional Skin and Healthy Non-lesional Skin

Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males

Immune Metabolic Associations in Psoriatic Arthritis